A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Study Summary

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

Conditions

Achondroplasia

Interventions / Drugs

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment22 participants

Primary Completion—

Lead SponsorAscendis Pharma Growth Disorders A/S

Data Retrieved2026-04-11 02:54:40.919403+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.